Department of Proteomics in Cancer, Institute of Cancer Biology, Danish Cancer Society, Copenhagen, Denmark.
Mol Oncol. 2010 Dec;4(6):539-61. doi: 10.1016/j.molonc.2010.09.005. Epub 2010 Oct 8.
Our limited understanding of the biological impact of the whole spectrum of early breast lesions together with a lack of accurate molecular-based risk criteria for the diagnosis and assignment of prognostic significance to biopsy findings presents an important problem in the clinical management of patients harboring precancerous breast lesions. As a result, there is a need to identify biomarkers that can better determine the outcome of early breast lesions by identifying subpopulations of cells in breast premalignant disease that are at high-risk of progression to invasive disease. A first step towards achieving this goal will be to define the molecular phenotypes of the various cell types and precursors - generated by the stem cell hierarchy - that are present in normal and benign conditions of the breast. To date there have been very few systematic proteomic studies aimed at characterizing the phenotypes of the different cell subpopulations present in normal human mammary tissue, partly due to the formidable heterogeneity of mammary tissue, but also due to limitations of the current proteomic technologies. Work in our laboratories has attempted to address in a systematic fashion some of these limitations and here we present our efforts to search for biomarkers using normal fresh tissue from non-neoplastic breast samples. From the data generated by the 2D gel-based proteomic profiling we were able to compile a protein database of normal human breast epithelial tissue that was used to support the biomarker discovery program. We review and present new data on the putative cell-progenitor marker cytokeratin 15 (CK15), and describe a novel marker, dihydropyriminidase-related protein 3 (DRP3) that in combination with CK15 and other well known proteins were used to define molecular phenotypes of normal human breast epithelial cells and their progenitors in resting acini, lactating alveoli, and large collecting ducts of the nipple. Preliminary results are also presented concerning DRP3 positive usual ductal hyperplasias (UDHs) and on single cell layer columnar cells (CCCs). At least two bona fide biomarkers of undifferentiated ERα/PgR negative luminal cells emerged from these studies, CK15 and c-KIT, which in combination with transformation markers may lead to the establishment of a protein signature able to identify breast precancerous at risk of progressing to invasive disease.
我们对整个早期乳腺癌病变范围的生物学影响的认识有限,并且缺乏准确的基于分子的风险标准来诊断和分配活检结果的预后意义,这在患有癌前病变的患者的临床管理中是一个重要问题。因此,需要确定生物标志物,通过鉴定乳腺前病变中具有进展为浸润性疾病高风险的细胞亚群,更好地确定早期乳腺癌病变的结果。实现这一目标的第一步将是定义存在于正常和良性乳腺状态下的各种细胞类型和前体细胞(由干细胞层次产生)的分子表型。迄今为止,针对正常人类乳腺组织中存在的不同细胞亚群的表型进行的系统蛋白质组学研究很少,部分原因是乳腺组织的异质性很大,但也由于当前蛋白质组学技术的局限性。我们实验室的工作试图以系统的方式解决其中的一些限制,在这里我们介绍了使用非肿瘤性乳腺样本的新鲜正常组织来寻找生物标志物的努力。从基于 2D 凝胶的蛋白质组 profiling 生成的数据中,我们能够编译一个正常人类乳腺上皮组织的蛋白质数据库,该数据库用于支持生物标志物发现计划。我们回顾并提出了关于假定的细胞祖细胞标志物角蛋白 15(CK15)的新数据,并描述了一种新型标志物,二氢嘧啶酶相关蛋白 3(DRP3),它与 CK15 和其他已知蛋白一起用于定义静止小泡、泌乳肺泡和乳头大收集管中的正常人类乳腺上皮细胞及其祖细胞的分子表型。还介绍了关于 DRP3 阳性的普通导管增生(UDH)和单细胞层柱状细胞(CCC)的初步结果。这些研究至少出现了两种未分化的 ERα/PgR 阴性腔细胞的真正生物标志物,CK15 和 c-KIT,它们与转化标志物结合使用可能导致建立能够识别具有进展为浸润性疾病风险的癌前病变的蛋白质特征。